论文部分内容阅读
目的:探讨米非司酮及达那唑用于盆腔子宫内膜异位症(以下简称内异症)术后辅助治疗的疗效及安全性。方法:回顾分析了136例盆腔内异症患者术后随访资料,比较术后应用米非司酮、达那唑及未用药组的复发率及药物副反应。结果:米非司酮组、达那唑组复发率分别为3.92%、10.53%,低于未用药组34.04%(P<0.05,P<0.05)。米非司酮组肝功损害发生率3.92%显著低于达那唑组39.47%。结论:米非司酮、达那唑用于盆腔内异症的术后辅助治疗是有效的,米非司酮副反应较少。
Objective: To investigate the efficacy and safety of mifepristone and danazol for postoperative adjuvant therapy of pelvic endometriosis (hereinafter referred to as endometriosis). Methods: A retrospective analysis of 136 patients with pelvic endometriosis follow-up data were compared postoperative application of mifepristone, danazol and no drug group, the recurrence rate and adverse drug reactions. Results: The recurrence rates of mifepristone group and danazol group were 3.92% and 10.53%, respectively, which were lower than 34.04% (P <0.05, P <0.05). The incidence of liver damage in mifepristone group was significantly lower than that in danazol group by 3.92% and 39.47% respectively. Conclusion: Mifepristone and danazol are effective in the postoperative adjuvant therapy of pelvic endometriosis with less side effects of mifepristone.